NCT05235347
Sotrovimab Expanded Access Treatment Protocol (COVID-19)
Sotrovimab Expanded Access Treatment Protocol
Vir Biotechnology, Inc.·ClinicalTrials.gov·biologicalNo longer available
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Covid19
- Drug/Device/Intervention
- Sotrovimab
- Study type
- Expanded access
- Intervention type
- biological
Sponsor & location
- Primary sponsor
- Vir Biotechnology, Inc.
- Location
- Palo Alto,Boston,Saint Louis,Seattle, United States of America
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Summary
An expanded access program for sotrovimab administered intravenously to participants with
 COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.
ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteRift Valley feverPlague
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05235347
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05235347 through Pure Global AI's free database. This phase not specified trial is sponsored by Vir Biotechnology, Inc. and is currently No longer available. The study focuses on Covid19.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.